11. Sehn L. The impact of R-CHOP on survival in aggressive NHL. The role of immunotherapy in NHL : optimising treatment outcomes. Investigator update and expert forum. 2004, Abstract book : 8

12. Pfreundschuh M.G, Trümper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab – early stopping after the first interim analysis. Proc Am Soc Clin Oncol 2004, Abstract No: 6500

13. Hiddemann W, Dreyling M, Unterhalt M, et al. Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc Am Soc Clin Oncol 2004, Abstract No: 6501

14. Drach J, Kaufmann H, Woehrer S, et al. Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma. Proc Am Soc Clin Oncol 2004, Abstract No: 6583

15. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003, 101(2):420-4

16. Czuczman M. S. Interim results from a phase I/II study of anti-CD80 antibody (IDEC-114) therapy for follicular NHL.Meeting: Proc Am Soc Clin Oncol 2003, Abstract No: 2310

17. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\'s lymphoma. J Clin Oncol. 2002, 20(10):2453-63

18. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol. 2002, 20(16):3545-57

19. Leonard, JP, Coleman M, Kostakoglu L, et al. Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol 2004, Abstract No: 6518

20. Shipley DL, Spigel DR, Carrell DL, et al. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2004, Abstract No: 6519

21. Link B, Kaminiski MS, Coleman M, et al. Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol 2004, Abstract No: 6520

22. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood. 1997, 1;89(9):3129-35

23. Timmerman JM, Singh G, Hermanson G, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002, 15;62(20):5845-52